Both animal models and human observational and genetic studies have shown that immune
and inflammatory mechanisms play a key role in hypertension and its complications. We …

Calcineurin inhibitors (CNIs) revolutionized the field of organ transplantation and remain the
standard of care 40 years after the discovery of cyclosporine. The early impressive results of …

Background In previous analyses of BENEFIT, a phase 3 study, belatacept-based
immunosuppression, as compared with cyclosporine-based immunosuppression, was …

The long-term management of maintenance immunosuppression in kidney transplant
recipients remains complex. The vast majority of patients are treated with the calcineurin …

Epstein–Barr virus (EBV) is an important pathogen in recipients of solid organ transplants
(SOT). Infection with EBV manifests as a spectrum of diseases/malignancies ranging from …

Advances in immunosuppression have propelled kidney transplantation from a scientific
curiosity to the optimal treatment for patients with end stage kidney disease. Declining rates …

The clinical profile of belatacept in kidney transplant recipients was evaluated to determine if
earlier results in the BENEFIT study were sustained at 3 years. BENEFIT is a randomized 3 …

The prevalent renal transplant population presents an opportunity to observe the adaptive
changes in the alloimmune response over time, but such studies have been limited by …

Background: There is no doubt that acute calcineurin inhibitor (CNI) nephrotoxicity exists;
however, chronic CNI nephrotoxicity is questionable at best. Methods: We reviewed the …

Background: Open Access Editor's Choice Review Risk Factors of Rejection in Renal
Transplant Recipients: A Narrative Review by Hani Oweira 1, Ali Ramouz 2, Omid …